Wolszczak-Biedrzycka Blanka, Dorf Justyna, Wojewódzka-Żelezniakowicz Marzena, Żendzian-Piotrowska Małgorzata, Dymicka-Piekarska Violetta Joanna, Matowicka-Karna Joanna, Maciejczyk Mateusz
Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Olsztyn, 10-900, Poland.
Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Bialystok, 15-089, Poland.
J Inflamm Res. 2023 Dec 11;16:6055-6070. doi: 10.2147/JIR.S439217. eCollection 2023.
In coronavirus disease (COVID-19), inflammation takes center stage, with a cascade of cytokines released, contributing to both inflammation and lung damage. The objective of this study is to identify biomarkers for diagnosing and predicting the severity of COVID-19.
Cytokine levels were determined in the serum from venous blood samples collected from 100 patients with COVID-19 and 50 healthy controls. COVID-19 patients classified based on the Modified Early Warning (MEWS) score. Cytokine concentrations were determined with a multiplex ELISA kit (Bio-Plex Pro™ Human Cytokine Screening Panel).
The concentrations of all analyzed cytokines were elevated in the serum of COVID-19 patients relative to the control group, but no significant differences were observed in interleukin-9 (IL-9) and IL-12 p70 levels. In addition, the concentrations of IL-1α, IL-1β, IL-1ra, IL-2Rα, IL-6, IL-12 p40, IL-18, and tumor necrosis factor alpha (TNFα) were significantly higher in symptomatic patients with accompanying pneumonia without respiratory failure (stage 2) than in asymptomatic/mildly symptomatic patients (stage 1).
The study revealed that IL-1ra, IL-2Rα, IL-6, IL-8, IL-12 p40, IL-16, and IL-18 levels serve as potential diagnostic biomarkers in COVID-19 patients. Furthermore, elevated IL-1α levels proved to be valuable in assessing the severity of COVID-19.
在冠状病毒病（COVID-19）中，炎症处于核心地位，一系列细胞因子被释放出来，导致炎症和肺损伤。本研究的目的是确定用于诊断和预测COVID-19严重程度的生物标志物。
测定了从100例COVID-19患者和50名健康对照者采集的静脉血样本血清中的细胞因子水平。COVID-19患者根据改良早期预警（MEWS）评分进行分类。细胞因子浓度用多重ELISA试剂盒（Bio-Plex Pro™ 人细胞因子筛选试剂盒）测定。
与对照组相比，COVID-19患者血清中所有分析的细胞因子浓度均升高，但白细胞介素-9（IL-9）和IL-12 p70水平未观察到显著差异。此外，伴有肺炎但无呼吸衰竭的有症状患者（2期）血清中IL-1α、IL-1β、IL-1ra、IL-2Rα、IL-6、IL-12 p40、IL-18和肿瘤坏死因子α（TNFα）的浓度显著高于无症状/轻度有症状患者（1期）。
该研究表明，IL-1ra、IL-2Rα、IL-6、IL-8、IL-12 p40、IL-16和IL-18水平可作为COVID-19患者潜在的诊断生物标志物。此外，升高的IL-1α水平在评估COVID-19严重程度方面被证明具有重要价值。
